Savior Lifetec Corporation is a pharmaceutical company specializing in the research, development, and production of generic drugs. The company focuses on therapeutic areas including cardiovascular, respiratory, and nervous system disorders. It manufactures carbapenem antibiotics, utilizing vertical integration that spans from active pharmaceutical ingredient manufacturing to finished dosage forms. Savior Lifetec provides contract development and manufacturing services, including formulation development, quality control, production, and regulatory affairs support. The company holds GMP certifications and has passed audits by the US FDA and the European Medicines Agency. Its products are registered with health authorities in various markets, and the company serves global customers through its pharmaceutical value chain services.
More
Summarised from the company's own disclosures, fiscal year ended Oct 2026
Industry
Drug Manufacturers - Specialty & Generic
Homepage
saviorlifetec.com.tw
Sector
Healthcare
IR page
—
Tags
generic drugs, carbapenem antibiotics, cardiovascular, respiratory system, nervous system, contract manufacturing, formulation development, quality control, regulatory affairs, active pharmaceutical ingredients, Savior Lifetec Corporation
More
Press page
—
Metrics
Market cap
NT$ 5.589B
Market cap (USD)
$ 169.628M
P/E
6.51
PEG
0.04
P/BV
1.30
P/S
4.83
P/OCF
10.78
P/FCF
—
Dividend yield
—
Turnover / mcap
—
ROE
14.7%
ROI
14.2%
ROIC
4.8%
Profit margin
44.7%
Revenue growing
No
Profits growing
Yes
Revenue up 3y
No
Revenue up 5y
No
Earnings growth 3y (net profit CAGR)
145.4%
Profitable
Yes
Margin expanding
Yes
Buying back stock
Yes
Diluting (TTM)
Yes
Debt/Equity
—
Podcast bulls (TTM)
Sign up
Podcast bears (TTM)
Sign up
Podcast sentiment (TTM)
Sign up
Podcast sentiment % (TTM)
Sign up
News sentiment (TTM)
0
Quality score
25.0%
Buys, 1w
Sign up
Buys, 1m
Sign up
Buys, 1y
Sign up
Sells, 1w
Sign up
Sells, 1m
Sign up
Sells, 1y
Sign up
Sign up to see this company's insider trades
Fundamentals
(all numbers in TWD)
Compare
All 27 figures
Annual
Quarterly
Compare with
×
Revenue
1.202B
1.217B
1.05B
1.266B
1.744B
1.827B
1.319B
1.105B
1.618B
1.532B
1.121B
1.019B
1.001B
Net profit
537.449M
182.38M
30.03M
36.387M
9.956M
250.941M
-4.934M
-359.547M
22.273M
-207.697M
-493.793M
-355.79M
-228.703M
Share price
18.4
—
—
—
—
—
—
—
—
—
—
—
—
P/S
4.75
—
—
—
—
—
—
—
—
—
—
—
—
Sign up to see institutional holdings
Sign Up
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up
Material information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS. Press releases from the company's own website, newest first.
AI comment
This is a routine notice announcing the date and format of an upcoming online investor relations meeting. It provides no new financial data, guidance, or operational updates, and thus has no impact on company value.
AI comment
This is a routine regulatory filing announcing that the board of directors has approved the company's third-quarter consolidated financial statements. It is a formal notice of completion of internal approval procedures and does not contain new substantive information about value drivers or performance surprises.
AI comment
This is a routine filing confirming that the board has approved the Q3 consolidated financial statements. The approval of financial reports is a standard procedural step that conveys no new information regarding value or performance.
AI comment
This is a routine regulatory filing confirming that the board of directors has approved the company's interim financial report for the first half of the year. It serves as a procedural notice and does not contain new substantive information or analysis of the results' quality relative to expectations.
AI comment
This is a routine board resolution filing approving the Q2 financial report, removing director competition restrictions, updating shareholder meeting rules, approving the sustainability report, and authorizing manager bonuses. These are standard corporate governance and administrative matters that provide no new information regarding the company's value or future performance.
AI comment
This is a routine administrative notice announcing the scheduled date for the board meeting to review the Q2 financial results. It provides no financial data or strategic developments, only procedural information.
AI comment
This is a routine administrative filing announcing the record date, ex-dividend date, and distribution schedule for a previously approved cash dividend and share issuance. It provides no new information regarding the company's value or performance.
AI comment
The board approved a cash dividend distribution and capitalization of surplus via new share issuance. This is a positive capital return action, though the specific amounts are not detailed in the text, warranting a modest bullish score.
AI comment
The company received GMP certification for a new line of its active pharmaceutical ingredient (meropenem). This is a positive operational milestone that validates production capability and may facilitate future sales, but it does not represent a confirmed order or immediate revenue impact.
AI comment
This is a routine regulatory filing announcing that the Annual General Meeting approved existing directors to engage in competing business activities. This is a standard corporate governance formality that does not convey new information about the company's value or performance.
AI comment
The company announced the reappointment of the same three independent directors to the Remuneration Committee following the expiration of their terms. This is a routine governance filing with no new strategic or financial implications for shareholder value.
AI comment
Routine board appointment where the outgoing and incoming chairman are the same representative of the same entity, resulting in no change in leadership or strategy.
AI comment
Routine board resolutions appointing a new chairman and salary committee members; no new operational or financial information affecting value.
AI comment
Routine filing announcing the appointment of representatives for corporate directors following the annual general meeting; no new information affecting company value.
AI comment
This is a routine administrative filing regarding the expiration of terms and reappointment of audit committee members following a general board renewal. It involves no change in personnel or strategy and conveys no new information about company value.
AI comment
This is a routine filing announcing the expiration of terms and the full re-election of the board of directors at the annual general meeting. The changes are standard corporate governance procedures with no new strategic direction or contested decisions that would impact company value.
AI comment
This is a routine filing of the resolutions from the Annual General Meeting, including the approval of the previous year's financial statements, dividend distribution, and routine board elections. These are formalities that do not convey new information about the company's value or future prospects.
AI comment
This is a routine administrative filing correcting minor content in the annual general meeting handbook. It is a formal notice with no impact on company value or financial performance.
AI comment
The item is a routine notice inviting attendees to a trade show (CPHI China 2026), which provides no new financial or operational information affecting company value.
AI comment
The company is investing TWD 300 million (approx. 8% of its TWD 3.78B equity) into a 100% owned subsidiary to fund business expansion and working capital. This is a routine internal capital allocation decision using existing funds, indicating modest growth intent without dilution or significant risk, hence a minor bullish score.
AI comment
This is a routine filing regarding a cash capital increase by a subsidiary (Hanrui Investment), not the parent company Savior Lifetec. The event concerns the subsidiary's internal capital structure and does not directly impact the parent's equity value or share price.
Show all 21 news items
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat.
Shared by
Asian Century Stocks and
Uncovered Thai Stocks .
Thank you.
Base
Enforce Recency
Overview
Bull Bear
Competitive Advantages
Supply Chain
Segments
Earnings Results
Earnings Calls
Management
Stock Price Analysis
Comps
Forward Projection
Red Flags
Management Questions
Devils Advocate
Constraints
Share Value Compliance
Equity Research
Savior Lifetec Corporation (ticker 4167.TWO), listed in Taiwan.
Copy
Clear
Copied
ETFs Holding Savior Lifetec Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
AVEE
0.01%
27,768
$ 15.221K
Nov 16, 2026
DEXC
0.01%
32,244
$ 18.582K
Nov 12, 2026
DFEV
0.00%
122,820
$ 70.78K
Nov 12, 2026
DFEM
0.00%
385,548
$ 222.188K
Nov 12, 2026
DFAE
0.00%
303,312
$ 174.796K
Nov 12, 2026
DFAX
0.00%
220,711
$ 127.194K
Nov 12, 2026
AVEM
0.00%
159,132
$ 87.228K
Nov 16, 2026
AVSE
0.00%
5,340
$ 2,927.11
Nov 16, 2026
AVXC
0.00%
1,068
$ 585.42
Nov 16, 2026